{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:16:35Z","timestamp":1793927795055,"version":"4.8.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Systemic glucocorticosteroids (SGCs) are used in the short-term treatment of atopic dermatitis (AD), but are not recommended for long-term use because they are associated with severe side-effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study aimed to characterize the utilization and potentially negative effects of SGC use for AD in German statutory health insurance (SHI) claims data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Cross-sectional and longitudinal analysis of a large nationwide SHI dataset. SGC drug prescriptions and incidences of predefined comorbidities after drug initiation that were known to be potentially harmful side-effects were analysed. SGC use was quantified by (\u00addefinition\u00a01) the number of quarters with at least one SGC prescription and (definition 2) the defined daily doses (DDD). Comparisons were adjusted for age, sex and morbidity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The AD prevalence was 4.07% in 2020 (4.12% women, 3.42% men). During this period 9.91% of people with AD were prescribed SGCs compared with 5.54% in people without AD (P &amp;lt; 0.01). Prescribing of SGCs was significantly higher in women (10.20% vs. 9.42% in men, P &amp;lt; 0.01) and in the elderly. AD and SGC prevalence varied regionally. In a 3-year follow-up period, 58% of people with AD receiving a SGC were prescribed SGCs in &amp;gt; one quarter and 15% in &amp;gt; six quarters. The odds of developing osteoporosis [odds ratio (OR) 3.90 \u00ad(definition\u00a01) and 1.80 (definition 2)] and diabetes [OR 1.90 (definition 1) and 1.38 (definition 2)] were significantly higher in people with AD on SGCs, especially in the frequently prescribed group compared with the rarely prescribed group, regardless of quantified use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A considerable number of people with AD in Germany are prescribed long-term SGCs. The onset of medical conditions known to be harmful effects of steroids was significantly more frequent in those who were frequently prescribed SGCs, indicating the need for optimized healthcare.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae250","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T14:58:41Z","timestamp":1719413921000},"page":"719-727","source":"Crossref","is-referenced-by-count":12,"title":["Utilization and related harms of systemic glucocorticosteroids for atopic dermatitis: claims data analysis"],"prefix":"10.1093","volume":"191","author":[{"given":"Kristina","family":"Hagenstr\u00f6m","sequence":"first","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE) , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Klinger","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE) , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE) , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Willers","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE) , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE) , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"2024102112263299500_ljae250-B1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2147\/CLEP.S315888","article-title":"Prevalence and medications of atopic dermatitis in Germany: claims data analysis","volume":"13","author":"Hagenstr\u00f6m","year":"2021","journal-title":"Clin Epidemiol"},{"key":"2024102112263299500_ljae250-B2","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00105-021-04885-3","article-title":"Qualit\u00e4t der dermatologischen Versorgung von Neurodermitis in Deutschland \u2013 keine Verbesserung der Indikatoren nach 10 Jahren","volume":"72","author":"Langenbruch","year":"2021","journal-title":"Hautarzt"},{"key":"2024102112263299500_ljae250-B3","doi-asserted-by":"crossref","first-page":"adv00830","DOI":"10.2340\/actadv.v102.3932","article-title":"Real-world treatment patterns and treatment benefits among adult patients with atopic dermatitis: results from the atopic dermatitis patient satisfaction and unmet need survey","volume":"102","author":"Augustin","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"2024102112263299500_ljae250-B4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1080\/09546634.2017.1365112","article-title":"Prescriptions for atopic dermatitis: oral corticosteroids remain commonplace","volume":"29","author":"Alexander","year":"2018","journal-title":"J\u00a0Dermatolog Treat"},{"key":"2024102112263299500_ljae250-B5","first-page":"49","article-title":"Usage and effectiveness of systemic treatments in adults with severe atopic eczema: first results of the German Atopic Eczema Registry TREATgermany","volume":"15","author":"Schmitt","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"key":"2024102112263299500_ljae250-B6","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/bjd.15235","article-title":"Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists","volume":"176","author":"Taylor","year":"2017","journal-title":"Br J Dermatol"},{"key":"2024102112263299500_ljae250-B7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/978-1-84800-165-7_32","volume-title":"Clinical and Basic Immunodermatology","author":"Hengge","year":"2008"},{"key":"2024102112263299500_ljae250-B8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40264-015-0287-7","article-title":"Topical corticosteroid-induced skin atrophy: a comprehensive review","volume":"38","author":"Barnes","year":"2015","journal-title":"Drug Saf"},{"key":"2024102112263299500_ljae250-B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2016.01.062","article-title":"Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health","volume":"76","author":"Caplan","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2024102112263299500_ljae250-B10","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"2024102112263299500_ljae250-B11","doi-asserted-by":"crossref","first-page":"e015905","DOI":"10.1136\/bmjopen-2017-015905","article-title":"Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France","volume":"7","author":"B\u00e9nard-Laribi\u00e8re","year":"2017","journal-title":"BMJ Open"},{"key":"2024102112263299500_ljae250-B12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaip.2021.09.026","article-title":"Atopic eczema-associated fracture risk and oral corticosteroids: a population-based cohort study","volume":"10","author":"Matthewman","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102112263299500_ljae250-B13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/bcp.14679","article-title":"Is there a safe and effective way to wean patients off long-term glucocorticoids?","volume":"87","author":"Baker","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2024102112263299500_ljae250-B14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jaad.2017.09.074","article-title":"A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis","volume":"78","author":"Yu","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2024102112263299500_ljae250-B15","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European Guideline (EuroGuiDerm) on Atopic Eczema: part I \u2013 systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024102112263299500_ljae250-B16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-1-4614-9191-0_5","volume-title":"Health Care Utilization in Germany: Theory, Methodology, and Results","author":"Swart","year":"2014","edition":"1st edn"},{"key":"2024102112263299500_ljae250-B17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10654-019-00500-x","article-title":"Guidelines and recommendations for ensuring Good Epidemiological Practice (GEP): a guideline developed by the German Society for Epidemiology","volume":"34","author":"Hoffmann","year":"2019","journal-title":"Eur J Epidemiol"},{"key":"2024102112263299500_ljae250-B18","doi-asserted-by":"crossref","first-page":"\u200b656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2024102112263299500_ljae250-B19","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/MLR.0b013e31819432e5","article-title":"A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data","volume":"47","author":"van Walraven","year":"2009","journal-title":"Med Care"},{"key":"2024102112263299500_ljae250-B20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/jdv.13813","article-title":"Prevalence and comorbidities in adults with psoriasis compared to atopic eczema","volume":"31","author":"Radtke","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024102112263299500_ljae250-B21","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/j.1440-0960.1996.tb01070.x","article-title":"Compliance problems in paediatric atopic eczema","volume":"37","author":"Fischer","year":"1996","journal-title":"Australas J Dermatol"},{"key":"2024102112263299500_ljae250-B22","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1046\/j.1365-2133.2000.03473.x","article-title":"Topical corticosteroid phobia in patients with atopic eczema","volume":"142","author":"Charman","year":"2000","journal-title":"Br J Dermatol"},{"key":"2024102112263299500_ljae250-B23","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1080\/08035250600612298","article-title":"Steroid fears in children with eczema","volume":"95","author":"Hon","year":"2006","journal-title":"Acta Paediatr"},{"key":"2024102112263299500_ljae250-B24","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1365-2133.2011.10449.x","article-title":"Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency","volume":"165","author":"Aubert-Wastiaux","year":"2011","journal-title":"Br J Dermatol"},{"key":"2024102112263299500_ljae250-B25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1525-1470.2012.01808.x","article-title":"Factors associated with steroid phobia in caregivers of children with atopic dermatitis","volume":"30","author":"Kojima","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"2024102112263299500_ljae250-B26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol Bull"},{"key":"2024102112263299500_ljae250-B27","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1161\/CIRCULATIONAHA.106.672402","article-title":"Use and misuse of the receiver operating characteristic curve in risk prediction","volume":"115","author":"Cook","year":"2007","journal-title":"Circulation"},{"key":"2024102112263299500_ljae250-B28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1055\/s-0031-1275711","article-title":"Structural differences between health insurance funds and their impact on health services research: results from the Bertelsmann Health-Care Monitor","volume":"74","author":"Hoffmann","year":"2012","journal-title":"Gesundheitswesen"},{"key":"2024102112263299500_ljae250-B29","first-page":"45","article-title":"Prevalence of psoriasis and psoriatic arthritis in Germany \u2013 analysis of claims data","volume":"22","author":"Hagenstr\u00f6m","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"2024102112263299500_ljae250-B30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.zefq.2019.02.004","article-title":"Internal diagnostic validation of patients with a chronic wound: possibilities of identification on the basis of routine data","volume":"140","author":"Hagenstr\u00f6m","year":"2019","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"key":"2024102112263299500_ljae250-B31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"2024102112263299500_ljae250-B32","first-page":"120","article-title":"Good Practice of Secondary Data Analysis (GPS): guidelines and recommendations","volume":"77","author":"Swart","year":"2015","journal-title":"Gesundheitswesen"},{"key":"2024102112263299500_ljae250-B33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jaad.2005.03.029","article-title":"Socioeconomic status influences care of patients with acne in Ontario, Canada","volume":"54","author":"Haider","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2024102112263299500_ljae250-B34","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"key":"2024102112263299500_ljae250-B35","doi-asserted-by":"crossref","first-page":"152010","DOI":"10.1016\/j.semarthrit.2022.152010","article-title":"The glucocorticoid toxicity index: measuring change in glucocorticoid toxicity over time","volume":"55","author":"Stone","year":"2022","journal-title":"Semin Arthritis Rheum"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae250\/58869131\/ljae250.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/5\/719\/59927245\/ljae250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/5\/719\/59927245\/ljae250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T12:27:02Z","timestamp":1729513622000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/191\/5\/719\/7699816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,6,27]]},"published-print":{"date-parts":[[2024,10,17]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae250","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,6,27]]}}}